Medpace Holdings Inc vs Solaredge Technologies Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Solaredge Technologies Inc trades at $32.21 (market cap $2.00B). The key difference: Medpace Holdings Inc is far larger — about 8.4× Solaredge Technologies Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Solaredge Technologies Inc for 34 Days on average.
| MEDP | SEDG | |
|---|---|---|
Market Cap | $16.82B | $2.00B |
Volume | 223,093 | 2,739,860 |
Sector | Health | Energy |
52-Week High | $630.19 | $78.51 |
52-Week Low | $393.42 | $28.47 |
Typical Hold Time | 14 Days | 34 Days |
Enterprise Value | $16.44B | $1.86B |
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
SolarEdge Technologies (SEDG) trades at $32.47, down 2.08% amid bearish technical signals and ongoing financial challenges. The company reported a net loss of $405 million in 2025 with negative profit margins, though revenue showed some recovery to $1.18 billion. Recent news highlights multiple law firm investigations into investor claims while the company pursues AI data center expansion opportunities.
The outlook remains challenging with significant execution risks and negative profitability, though analyst consensus suggests modest upside potential to the $37.75 price target. Key risks include ongoing legal scrutiny, competitive pressures in solar markets, and the company's ability to achieve its ambitious 2029 revenue target of $2.4 billion.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →